Antibody Drug Conjugate Market: By Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies) - Forecast 2027

Antibody Drug Conjugate Market Scenario

Antibody drug conjugates comprise three parts, mainly a specific antibody for binding, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the antibody. These drug conjugates are regarded to be the new age of therapeutic agents. The combine effect of targeting specific types of cells and the killing ability of cytotoxic drugs make this drug conjugate the ideal one for treatment of various cancers. The success of this technology has become possible only with increasing technological advancements. The potential of a cytotoxic drug embedded in the antibody drug conjugate is increased by 100–1000 fold more than the potential of cytotoxic drug when it acts alone.

The key antibody-drug conjugates currently under the clinical trial is glembatumumab vedotin (CDX-011), a monoclonal antibody-drug conjugate developed by Celldex Therapeutics Inc. Other drugs under clinical trials include Polatuzumab Vedotin (RG7596) developed by Roche/Genentech, Indatuximab Ravtansine (BT-062) developed by Biotest, Anti-guanylyl Cyclase C/Anti-GCC ADC developed by Takeda: Millennium, Anti-PSMA ADC Therapeutics developed by Progenics Pharmaceuticals; Coltuximab Ravtansine (SAR3419) developed by Sanofi, Pinatuzumab Vedotin (RG7593) developed by Roche/Genentech, and Lifastuzumab Vedotin (RG7599) developed by Roche/Genentech.

The advancement in the medical technology is driving the global market for antibody drug conjugates. Moreover, the rising cases of cancer, increase in obese population, and growing ageing population are some of the key driving factors for the market. Further over, preclinical research, the increasing research activities on antibody therapies, more research on advanced drug discoveries, increasing research on oncology diseases, the growing collaboration between research institutes, and biopharmaceuticals and biotechnology companies are acting as a fuel to the market and are expected to drive the market of antibody drug conjugates within the forecast period. However, the high cost of procedures and the lack of fund could be the restraints for the growth of this market.

The antibody drug conjugate market is expected to grow at a CAGR of approximately 19% during the forecast period, 2017–2023.

Research Methodology

 

Sources: Annual reports, Press release, White paper, and Company presentation

Segmentation

The global antibody drug conjugate market is segmented on the basis of type, product, technology, application, and end-user.  

On the basis of type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.

On the basis of application, the global antibody drug conjugate market is segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further divided into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).

On the basis of product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.

On the basis of technology, the global antibody drug conjugate market is classified into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.

On the basis of end-user, the global antibody drug conjugate market is classified into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others. 

Regional Analysis

The global antibody drug conjugate market consists of four regions, namely, America, Europe, Asia Pacific, and the Middle East and Africa.

Americas dominated the global antibody drug conjugate market owing to the technological innovation, advancement in manufacturing processes, contribution of nanotechnology for developing Antibody Drug Conjugates (ADC). There are only three antibody drug conjugates that have received approval from the U.S. Food and Drug Administration (FDA). The US is the largest market among other countries such as Mexico, Canada, and others. Though, this technology is being developed by many large pharmaceutical companies, the success rate is of developing an ADC very less and lies with very few companies.

The European antibody drug conjugate market is the second largest market followed by the Asia Pacific regions.

Asia Pacific is the emerging market in the global antibody drug conjugate market. The rising awareness among consumers along with growing government initiatives are driving the antibody drug conjugate market in this region. There are many products under the pipeline. These developments are carried out under license agreements.

Key Players

Some major players in the global antibody drug conjugate market include Seattle Genetics (US), ImmunoGen, Inc. (US), Roche Holding AG (Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany),  Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US), and others.

Intended Audience

• Antibody drug conjugate manufacturing companies


• Suppliers and distributors of antibody drug conjugate


• Healthcare service providers


• Health insurance players


• Research and consulting firms


• Medical research institutes


• Venture capitalists


• Community centers

Report Scope:

Report Attribute/Metric	Details
Market Size	Significant Value
CAGR	19%
Base Year	2017
Forecast Period	2027
Historical Data	2016
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors and Trends
Segments Covered	Type, product, technology, application, and end-user
Geographies Covered	North America, Europe, Asia-Pacific and Rest of the World (RoW)
Key Vendors	Seattle Genetics (US), ImmunoGen, Inc. (US), Roche Holding AG (Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US)
Key Market Opportunities	Research activities
Key Market Drivers	Advancement in the medical technology Obese population Growing ageing population

Frequently Asked Questions (FAQ) :

---